Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
US-2024252425-A1 · Aug 1, 2024 · US
US2018263902A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2018263902-A1 |
| Application number | US-201715463609-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 20, 2017 |
| Priority date | Mar 20, 2017 |
| Publication date | Sep 20, 2018 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
In one aspect the present invention features a process for making a tablet comprising the step of applying radiofrequency energy to a powder blend comprising lossy coated particles and at least one pharmaceutically active agent to sinter said powder blend into a tablet, said lossy coated particles comprising a substrate having a Q value of greater than 100 that is at least partially coated with a lossy coating comprising Hydrogenated Starch Hydrolysate.
Opening claim text (preview).
What is claimed is: 1 . A process for making a tablet comprising the step of applying radiofrequency energy to a powder blend comprising lossy coated particles and at least one pharmaceutically active agent to sinter said powder blend into a tablet, said lossy coated particles comprising a substrate having a Q value of greater than 100 that is at least partially coated with a lossy coating comprising Hydrogenated Starch Hydrolysate. 2 . A process of claim 1 , wherein said substrate has a Q value of greater than 200. 3 . (canceled) 4 . A process of claim 1 , wherein said lossy coated particles have a Q value of greater than 100. 5 . A process of claim 1 , wherein said powder blend has a Q value of greater than 100. 6 . A process of claim 1 , wherein said powder blend comprises at least 20%, by weight, of said lossy coated particles. 7 . A process of claim 1 , wherein said lossy coated particles comprise from about 0.1 to about 2%, by weight, of Hydrogenated Starch Hydrolysate. 8 . A process of claim 1 , wherein said lossy coated particle comprises from about 0.1% to about 3%, by weight, water. 9 . A process of claim 1 , wherein said tablet disintegrates in the mouth when placed on the tongue in less than about 30 seconds. 10 . A process of claim 1 , wherein said tablet disintegrates in the mouth when placed on the tongue in less than about 15 seconds. 11 . The process of claim 1 , wherein said radiofrequency energy has a frequency of from about 13 MHz to about 40 MHz. 12 . A process of claim 1 , wherein said tablets are formed within a tablet die. 13 . A process of claim 1 , wherein said substrate comprises a starch, a sugar alcohol, or a sugar. 14 . A process of claim 1 , wherein said substrate comprises maltitol or mannitol. 15 . A process of claim 1 , wherein said substrate comprises said pharmaceutically active agent. 16 . A process of claim 1 , wherein the friability of the tablet is less than about 5%. 17 . A process of claim 1 , wherein the hardness of the tablet is 1 kp or greater. 18 . A sintered tablet comprising sintered lossy coated particles and at least one pharmaceutically active agent, wherein said lossy coated particles comprise a substrate that is at least partially coated with a lossy coating comprising Hydrogenated Starch Hydrolysate, wherein said substrate has a Q value of greater than 100, said tablet having a hardness of 1 kp or greater and wherein said tablet disintegrates in the mouth when placed on the tongue in less than about 15 seconds. 19 . (canceled) 20 . (canceled) 21 . The process of claim 17 wherein said tablet disintegrates in the mouth when placed on the tongue in less than about 15 seconds. 22 . The process of claim 1 wherein said powder blend comprises lossy coated particles separate from said at least one pharmaceutically active agent.
Polysaccharides, e.g. gums, alginate; Cyclodextrin · CPC title
Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377) · CPC title
Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin · CPC title
Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)} · CPC title
Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.